Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

3 in the second quarter of 2008, compared to $109,153 in the second quarter of 2007. General and administrative expenses were $542,043, down from $988,233 in the second quarter of 2007.

Operating income was $2.8 million in the second quarter of 2008 compared to $3.6 million in the second quarter of 2007.

Net income for the second quarter of 2008 was $2.2 million, or $0.05 per diluted share, compared to $3.0 million, or $0.07 per fully diluted share, in the second quarter of 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $2.5 million, or $0.06 per fully diluted share, in the second quarter of 2008, compared to adjusted net income of $3.4 million, or $0.08 per fully diluted share, in the second quarter of 2007.

Six Month Financial Results

Revenues for the first six months of 2008 were $31.1 million, up 47.4% from revenues of $21.1 million in the first six months of 2007. Gross profit was $13.6 million, up 67.8% from gross profit of $8.1 million for the six months of 2007. Gross margin was 43.8%, compared to 38.5% for the first six months of 2007. Operating income was $4.3 million, compared to $4.8 million for the first six months of fiscal 2007.

Net income was $3.2 million, or $0.07 per fully diluted share, compared to $3.9 million, or $0.09 per fully diluted share, for the first six months of fiscal 2007.

Adjusting net income for non-cash financing costs associated with its convertible notes and convertible preferred stock, adjusted net income was $3.9 million, or $0.08 per fully diluted share, for the first six months of 2008, compared to adjusted net income of $4.4 million, or $0.10 per fully diluted share, for the first six months of 2007.

Financial Condition

As of June 30, 2008, Lotus had $3.4 million in cash and equivalents, and $27.0 million of working capital. Total assets were $49.0 million comp
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... DIEGO , Aug. 27, 2015 HUYA ... annual meeting of the Japan Society of HTLV-1, held ... Institute Auditorium. The purpose of the Society is to ... as the development of medical technology and research related ... and welfare. "HUYA is proud to support ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet ... a second US laboratory is to open in Manhattan, Kansas in early October, ... and long-term growth of research and development through collaboration with researchers from Kansas ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... -- WuXi PharmaTech (NYSE:,WX), China,s premier provider ... Governor Deval L. Patrick of the Commonwealth ... China,Partnership Official Delegation, paid a visit to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
... Systems, a leader in the field of,sleep diagnostic ... an,exclusive agreement with the Beth Israel Deaconess Medical ... Coupling (CPC) technology,developed by Drs. Robert Thomas, Ary ... technology represents a breakthrough in how sleep can ...
... Results to be presented at San Antonio Breast ... Agendia BV, world,leader in the rapidly evolving field ... consortium has demonstrated the,prognostic power of its MammaPrint(R) ... positive lymph nodes. The data show that,MammaPrint(R) can ...
Cached Biology Technology:Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 2Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 3Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 3
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... therapy has been identified by Monash University scientists investigating ... involved in cancer development. , A team led by ... has identified two proteins that are involved in stopping ... is essential if cancer cells are to proliferate. , ...
... the Nov. 24 issue of Science provide further support for ... new evidence that adult precursor cells from the spleen can ... and 2003, researchers at Massachusetts General Hospital (MGH) demonstrated the ... in diabetic mice. Three studies from other institutions published ...
... dolphin drive hunts begin in the Japanese villages of Taiji ... aquarium professionals has launched a campaign to end the practices ... Japan to put an end to the hunts. The "Act ... Emory University, and the World Association of Zoos and Aquariums ...
Cached Biology News:New target for cancer therapy identified 2New data from NIH lab confirms protocol to reverse type 1 diabetes in mice 2Renewed dolphin slaughter prompts new campaign 2Renewed dolphin slaughter prompts new campaign 3
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: